Evaluation of the New Variant 501Y.V2 of COVID-19 (VARICOVID)

Centre Hospitalier Régional Metz-Thionville

Status: Completed

Conditions: Covid19

Study type: Observational

Funder types: Other

Identifiers

NCT04906850

2021-05Obs-CHRMT

Details and patient eligibility

About

In January 2021, the incidence of COVID-19-and its mortality started rising for the third time in France. This rise may associate with three emerging variants, namely, V1, V2, and V3, which are the 20I/501Y.V1 ("English"), 20H/501Y.V2 ("South African"), and 20J/501Y.V3 ("Brazilian") variants, respectively. V1 was recently suggested to increase mortality in people in the United Kingdom who tested positive for COVID-19 on community screening. Very little is known about V2 infection, including its outcomes relative to other strains. In early 2021, V2 spread to the Grand-Est region (northeastern France). Here, the investigators aimed to report mortality data of patients admitted in ICU between February and April 2021 in 3 hospitals in Grand-Est: Metz, Thionville and Nancy.

Enrollment: 250 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Admission in ICU in February, March or April 2021
• Patient with a SARS-CoV-2 positive polymerase-chain reaction test
• Patient with 20I/501Y.V1 ("English") or 20H/501Y.V2 ("South African") SARS-CoV-2 variants

Exclusion criteria

• Opposed to use data